Search
LAX-101
go.drugbank.com/drugs/DB05301InvestigationalThe molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.
AAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalDeveloped by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalIf this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.
Ginger
go.drugbank.com/drugs/DB10344ApprovedInvestigationalGinger allergenic extract is used in allergenic testing.
Mixtures: Toe Corrector CompositeSilicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Mixtures: Advanced B & T Formula, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).
EGS21
go.drugbank.com/drugs/DB05056ExperimentalGC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders.
FINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalIt is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity … FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].